AbbVie Inc. (0QCV.L)

146,95 -0,42 (-0,28%) Alla chiusura: 07:14PM BST

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 50.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard A. Gonzalez	Chairman & CEO	7,19M	N/D	1954
Mr. Robert A. Michael	President & COO	4,62M	N/D	1970
Mr. Scott T. Reents	Executive VP & CFO	3,13M	N/D	1968
Dr. Azita Saleki-Gerhardt Ph.D.	Executive VP & COO	3,51M	5,25M	1963
Mr. Jeffrey Ryan Stewart	Executive VP & Chief Commercial Officer	4,32M	2,13M	1969
Dr. Thomas J. Hudson M.D.	Senior VP & Chief Scientific Officer of Global Research	N/D	N/D	1962
Ms. Elizabeth Shea	Senior Vice President of Investor Relations	N/D	N/D	N/D
Mr. Perry C. Siatis	Executive VP, General Counsel & Secretary	N/D	N/D	1975
Mr. Sanjay Narayan	Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal	N/D	N/D	N/D
Mr. Timothy J. Richmond	Executive VP & Chief Human Resources Officer	1,12M	N/D	1966

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Governance aziendale

L'ISS Governance QualityScore di AbbVie Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.